Quel est le prix pour Vertex Pharmaceuticals Incorporated (VRTX)

Le prix pour Vertex Pharmaceuticals Incorporated (VRTX) est $519.38

Quelle est la capitalisation boursière pour Vertex Pharmaceuticals Incorporated (VRTX)

La capitalisation boursière pour Vertex Pharmaceuticals Incorporated (VRTX) est $131.82B

Bénéfices de Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Année	Bénéfices	Changez
2026 (TTM)	$5.27B	13.60%
2025	$4.64B	1,768.49%
2024	$248.50M	-94.33%
2023	$4.38B	3.48%
2022	$4.23B	55.01%
2021	$2.73B	-12.40%
2020	$3.12B	123.45%
2019	$1.39B	132.39%
2018	$600.24M	-3,925.87%
2017	$-15.69M	-76.71%
2016	$-67.37M	-87.96%
2015	$-559.58M	-23.85%
2014	$-734.88M	-24.71%
2013	$-976.12M	7,783.99%
2012	$-12.38M	-120.48%
2011	$60.45M	-108.01%
2010	$-754.63M	17.51%
2009	$-642.18M	38.35%
2008	$-464.18M	8.73%
2007	$-426.91M	106.35%
2006	$-206.89M	19.32%
2005	$-173.39M	9.39%
2004	$-158.51M	-54.37%
2003	$-347.35M	190.28%
2002	$-119.66M	1.50%
2001	$-117.89M	119.92%
2000	$-53.61M	0.00%

Année

Bénéfices

Changez

2026 (TTM)

$5.27B

13.60%

2025

$4.64B

1,768.49%

2024

$248.50M

-94.33%

2023

$4.38B

3.48%

2022

$4.23B

55.01%

2021

$2.73B

-12.40%

2020

$3.12B

123.45%

2019

$1.39B

132.39%

2018

$600.24M

-3,925.87%

2017

$-15.69M

-76.71%

2016

$-67.37M

-87.96%

2015

$-559.58M

-23.85%

2014

$-734.88M

-24.71%

2013

$-976.12M

7,783.99%

2012

$-12.38M

-120.48%

2011

$60.45M

-108.01%

2010

$-754.63M

17.51%

2009

$-642.18M

38.35%

2008

$-464.18M

8.73%

2007

$-426.91M

106.35%

2006

$-206.89M

19.32%

2005

$-173.39M

9.39%

2004

$-158.51M

-54.37%

2003

$-347.35M

190.28%

2002

$-119.66M

1.50%

2001

$-117.89M

119.92%

2000

$-53.61M

0.00%

Entreprise	Bénéfices	Différence de bénéfices	Pays
Argenx SE ARGX.US	$1.95B	-63.02%	NL
CSL Limited CSL.AX	$-4.02B	-176.14%	AU
Moderna, Inc. MRNA.US	$-3.09B	-158.52%	US
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	$3.01B	-43.02%	BE

Entreprise

Bénéfices

Différence de bénéfices

Pays